Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Brian Kavanagh to Adult

This is a "connection" page, showing publications Brian Kavanagh has written about Adult.

 
Connection Strength
  
 
 
0.607
  
  1. Sheehan JP, Grills I, Chiang VL, Dong H, Berg A, Warnick RE, Kondziolka D, Kavanagh B. Quality of life outcomes for brain metastasis patients treated with stereotactic radiosurgery: pre-procedural predictive factors from a prospective national registry. J Neurosurg. 2019 12 01; 131(6):1848-1854.
    View in: PubMed
    Score: 0.036
  2. Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base. Urol Oncol. 2016 Apr; 34(4):165.e1-9.
    View in: PubMed
    Score: 0.029
  3. Amini A, Jones BL, Yeh N, Rusthoven CG, Armstrong H, Kavanagh BD. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):1052-63.
    View in: PubMed
    Score: 0.029
  4. Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, Bar?n AE, Yeh N, Gaspar LE, Liu AK, Ney DE, Damek DM, Lillehei KO, Kavanagh BD. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):894-902.
    View in: PubMed
    Score: 0.027
  5. Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e613-8.
    View in: PubMed
    Score: 0.023
  6. Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1066-74.
    View in: PubMed
    Score: 0.020
  7. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):112-8.
    View in: PubMed
    Score: 0.018
  8. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72.
    View in: PubMed
    Score: 0.017
  9. Poznanovic SA, Cass SP, Kavanagh BD. Short-term tumor control and acute toxicity after stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg. 2006 Mar; 134(3):437-42.
    View in: PubMed
    Score: 0.015
  10. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006; 45(7):848-55.
    View in: PubMed
    Score: 0.015
  11. Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 04; 178:103-107.
    View in: PubMed
    Score: 0.012
  12. Kavanagh BD, Fischer BA, Segreti EM, Wheelock JB, Boardman C, Roseff SD, Cardinale RM, Benedict SH, Goram AL. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2001 Oct 01; 51(2):435-41.
    View in: PubMed
    Score: 0.011
  13. Kavanagh BD, Segreti EM, Koo D, Amir C, Arthur D, Wheelock J, Cardinale RM, Schmidt-Ullrich RK. Long-term local control and survival after concomitant boost accelerated radiotherapy for locally advanced cervix cancer. Am J Clin Oncol. 2001 Apr; 24(2):113-9.
    View in: PubMed
    Score: 0.011
  14. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys. 2001 Mar 15; 49(4):1133-9.
    View in: PubMed
    Score: 0.010
  15. Vinogradskiy Y, Diot Q, Jones B, Castillo R, Castillo E, Kwak J, Bowles D, Grills I, Myziuk N, Guerrero T, Stevens C, Schefter T, Gaspar LE, Kavanagh B, Miften M, Rusthoven C. Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 04 01; 106(5):1063-1070.
    View in: PubMed
    Score: 0.010
  16. Wong DT, Gomez M, McGuire GP, Kavanagh B. Utilization of intensive care unit days in a Canadian medical-surgical intensive care unit. Crit Care Med. 1999 Jul; 27(7):1319-24.
    View in: PubMed
    Score: 0.009
  17. Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 10 01; 105(2):346-355.
    View in: PubMed
    Score: 0.009
  18. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.009
  19. Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019 07 01; 25(13):3946-3953.
    View in: PubMed
    Score: 0.009
  20. Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019; 19:100126.
    View in: PubMed
    Score: 0.009
  21. Amini A, Yeh N, Jones BL, Bedrick E, Vinogradskiy Y, Rusthoven CG, Amini A, Purcell WT, Karam SD, Kavanagh BD, Guntupalli SR, Fisher CM. Perioperative Mortality in Nonelderly Adult Patients With Cancer: A Population-based Study Evaluating Health Care Disparities in the United States According to Insurance Status. Am J Clin Oncol. 2018 05; 41(5):476-484.
    View in: PubMed
    Score: 0.009
  22. Stokes WA, Bronsert MR, Meguid RA, Blum MG, Jones BL, Koshy M, Sher DJ, Louie AV, Palma DA, Senan S, Gaspar LE, Kavanagh BD, Rusthoven CG. Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 01; 36(7):642-651.
    View in: PubMed
    Score: 0.008
  23. Robin TP, Camidge DR, Stuhr K, Nath SK, Breeze RE, Pacheco JM, Liu AK, Gaspar LE, Purcell WT, Doebele RC, Kavanagh BD, Rusthoven CG. Excellent Outcomes with Radiosurgery for Multiple?Brain Metastases in ALK and EGFR Driven?Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 05; 13(5):715-720.
    View in: PubMed
    Score: 0.008
  24. Trifiletti DM, Sheehan JP, Grover S, Dutta SW, Rusthoven CG, Kavanagh BD, Sahgal A, Showalter TN. National trends in radiotherapy for brain metastases at time of diagnosis of non-small cell lung cancer. J Clin Neurosci. 2017 Nov; 45:48-53.
    View in: PubMed
    Score: 0.008
  25. Stokes WA, Kavanagh BD, Raben D, Pugh TJ. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract Radiat Oncol. 2017 Jul - Aug; 7(4):270-278.
    View in: PubMed
    Score: 0.008
  26. Kavanagh BD, Gieschen HL, Schmidt-Ullrich RK, Arthur D, Zwicker R, Kaufman N, Goplerud DR, Segreti EM, West RJ. A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 1997 Jun 01; 38(3):561-8.
    View in: PubMed
    Score: 0.008
  27. Jackson MW, Palma DA, Camidge DR, Jones BL, Robin TP, Sher DJ, Koshy M, Kavanagh BD, Gaspar LE, Rusthoven CG. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol. 2017 04; 12(4):734-744.
    View in: PubMed
    Score: 0.008
  28. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.008
  29. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42.
    View in: PubMed
    Score: 0.008
  30. Amini A, Jones BL, Yeh N, Guntupalli SR, Kavanagh BD, Karam SD, Fisher CM. Disparities in disease presentation in the four screenable cancers according to health insurance status. Public Health. 2016 Sep; 138:50-6.
    View in: PubMed
    Score: 0.007
  31. Amini A, Jones BL, Jackson MW, Rusthoven CG, Maroni P, Kavanagh BD, Raben D. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy. 2016 Mar-Apr; 15(2):136-46.
    View in: PubMed
    Score: 0.007
  32. Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2016 May; 195(5):1453-1458.
    View in: PubMed
    Score: 0.007
  33. Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28; 10:218.
    View in: PubMed
    Score: 0.007
  34. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol. 2016 Jan 10; 34(2):123-9.
    View in: PubMed
    Score: 0.007
  35. Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol. 2015 Nov-Dec; 5(6):e589-e596.
    View in: PubMed
    Score: 0.007
  36. Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. 2015 Jun; 123(2):251-7.
    View in: PubMed
    Score: 0.007
  37. Brennan D, Schubert L, Diot Q, Castillo R, Castillo E, Guerrero T, Martel MK, Linderman D, Gaspar LE, Miften M, Kavanagh BD, Vinogradskiy Y. Clinical validation of 4-dimensional computed tomography ventilation with pulmonary function test data. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):423-9.
    View in: PubMed
    Score: 0.007
  38. Ney DE, Carlson JA, Damek DM, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol. 2015 Mar; 122(1):135-43.
    View in: PubMed
    Score: 0.007
  39. Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Jul; 16(7):1006-9.
    View in: PubMed
    Score: 0.007
  40. Reddy K, Gaspar LE, Kavanagh BD, Chen C. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. J Med Imaging Radiat Oncol. 2014 Dec; 58(6):714-21.
    View in: PubMed
    Score: 0.007
  41. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):892-8.
    View in: PubMed
    Score: 0.006
  42. Vinogradskiy Y, Diot Q, Kavanagh B, Schefter T, Gaspar L, Miften M. Spatial and dose-response analysis of fibrotic lung changes after stereotactic body radiation therapy. Med Phys. 2013 Aug; 40(8):081712.
    View in: PubMed
    Score: 0.006
  43. Reddy K, Gaspar LE, Kavanagh BD, Waziri A, Damek DM, Ney D, Lillehei KO, Chen C. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol. 2013 Aug; 114(1):111-6.
    View in: PubMed
    Score: 0.006
  44. Amin NP, Miften M, Thornton D, Ryan N, Kavanagh B, Gaspar LE. Effect of induction chemotherapy on estimated risk of radiation pneumonitis in bulky non-small cell lung cancer. Med Dosim. 2013; 38(3):320-6.
    View in: PubMed
    Score: 0.006
  45. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
    View in: PubMed
    Score: 0.006
  46. Howells CC, Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD, Miften M. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e441-6.
    View in: PubMed
    Score: 0.006
  47. Diot Q, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M. Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1024-30.
    View in: PubMed
    Score: 0.006
  48. Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):655-60.
    View in: PubMed
    Score: 0.006
  49. Kavanagh B, Anscher M, Leopold K, Deutsch M, Gaydica E, Dodge R, Allen K, Allen D, Staub W, Montana G, et al. Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990. Int J Radiat Oncol Biol Phys. 1992; 24(4):633-42.
    View in: PubMed
    Score: 0.006
  50. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34.
    View in: PubMed
    Score: 0.005
  51. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011 Sep 01; 117(17):4060-9.
    View in: PubMed
    Score: 0.005
  52. Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):51-7.
    View in: PubMed
    Score: 0.005
  53. Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):211-7.
    View in: PubMed
    Score: 0.005
  54. Zhang L, Kavanagh BD, Thorburn AM, Camidge DR. Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli. Clin Cancer Res. 2010 Sep 01; 16(17):4478-89.
    View in: PubMed
    Score: 0.005
  55. Flaig TW, Kondo KL, La Rosa FG, Kavanagh B, Crawford ED. A young woman with multiple kidney lesions. Oncology (Williston Park). 2010 Mar; 24(3):282-6.
    View in: PubMed
    Score: 0.005
  56. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):796-801.
    View in: PubMed
    Score: 0.005
  57. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009 Apr 01; 27(10):1579-84.
    View in: PubMed
    Score: 0.005
  58. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009 Apr 01; 27(10):1572-8.
    View in: PubMed
    Score: 0.005
  59. Schwer AL, Kavanagh BD, McCammon R, Gaspar LE, Kleinschmidt-De Masters BK, Stuhr K, Chen C. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1352-7.
    View in: PubMed
    Score: 0.004
  60. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1414-24.
    View in: PubMed
    Score: 0.004
  61. Ballonoff A, Kavanagh B, Nash R, Drabkin H, Trotter J, Costa L, Rabinovitch R. Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review. Acta Oncol. 2008; 47(5):962-70.
    View in: PubMed
    Score: 0.004
  62. Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008 Mar 15; 70(4):993-1001.
    View in: PubMed
    Score: 0.004
  63. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005 Aug 01; 62(5):1371-8.
    View in: PubMed
    Score: 0.004
  64. Arthur DW, Koo D, Zwicker RD, Tong S, Bear HD, Kaplan BJ, Kavanagh BD, Warwicke LA, Holdford D, Amir C, Archer KJ, Schmidt-Ullrich RK. Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):681-9.
    View in: PubMed
    Score: 0.003
  65. Manning MA, Cardinale RM, Benedict SH, Kavanagh BD, Zwicker RD, Amir C, Broaddus WC. Hypofractionated stereotactic radiotherapy as an alternative to radiosurgery for the treatment of patients with brain metastases. Int J Radiat Oncol Biol Phys. 2000 Jun 01; 47(3):603-8.
    View in: PubMed
    Score: 0.002
  66. Cardinale RM, Wu Q, Benedict SH, Kavanagh BD, Bump E, Mohan R. Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1999 Sep 01; 45(2):515-20.
    View in: PubMed
    Score: 0.002
  67. Arthur D, Kaufman N, Schmidt-Ullrich R, Kavanagh B, Simpson P, Hill M, Ali M. Heuristically derived tumor burden score as a prognostic factor for stage IIIB carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):743-51.
    View in: PubMed
    Score: 0.002
  68. Mak AC, Rich TA, Schultheiss TE, Kavanagh B, Ota DM, Romsdahl MM. Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid. Int J Radiat Oncol Biol Phys. 1994 Feb 01; 28(3):597-603.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)